{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:25:59Z","timestamp":1793190359219,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI68635"],"award-info":[{"award-number":["UM1 AI68635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI68614"],"award-info":[{"award-number":["UM1 AI68614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI68635"],"award-info":[{"award-number":["UM1 AI68635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R37AI054165"],"award-info":[{"award-number":["R37AI054165"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured two weeks post-dose two are assessed as correlates of risk and as correlates of protection against COVID-19. Analyses are conducted in the U.S. cohort of baseline SARS-CoV-2 negative per-protocol participants using a case-cohort design that measures the markers from all 12 vaccine recipient breakthrough COVID-19 cases starting 7 days post antibody measurement and from 639 vaccine recipient non-cases. All markers are inversely associated with COVID-19 risk and directly associated with vaccine efficacy. In vaccine recipients with nAb ID50 titers of 50, 100, and 7230 international units (IU50)\/ml, vaccine efficacy estimates are 75.7% (49.8%, 93.2%), 81.7% (66.3%, 93.2%), and 96.8% (88.3%, 99.3%). The results support potential cross-vaccine platform applications of these markers for guiding decisions about vaccine approval and use.<\/jats:p>","DOI":"10.1038\/s41467-022-35768-3","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T12:04:49Z","timestamp":1674129889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial"],"prefix":"10.1038","volume":"14","author":[{"given":"Youyi","family":"Fong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1546-6172","authenticated-orcid":false,"given":"Yunda","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-8343","authenticated-orcid":false,"given":"David","family":"Benkeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0333-5925","authenticated-orcid":false,"given":"Lindsay N.","family":"Carpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-3001","authenticated-orcid":false,"given":"Germ\u00e1n","family":"\u00c1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Dunkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iksung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Houchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Jayashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5496-8090","authenticated-orcid":false,"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Leith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne","family":"Haugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars W. P.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-2789","authenticated-orcid":false,"given":"Nima S.","family":"Hejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-3734","authenticated-orcid":false,"given":"April K.","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Andrasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-1036","authenticated-orcid":false,"given":"Maryam","family":"Keshtkar-Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana H.","family":"Beresnev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-2436","authenticated-orcid":false,"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-2714","authenticated-orcid":false,"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4073-0393","authenticated-orcid":false,"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Ake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3620-3059","authenticated-orcid":false,"given":"Cynthia L.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Kotloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben O.","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-9427","authenticated-orcid":false,"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Immune Assays Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Coronavirus Vaccine Prevention Network (CoVPN)\/2019nCoV-301 Principal Investigators and Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"United States Government (USG)\/CoVPN Biostatistics Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"35768_CR1","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech, C. et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320\u20132332 (2020).","journal-title":"N. Engl. J. Med."},{"key":"35768_CR2","doi-asserted-by":"publisher","first-page":"e1003769","DOI":"10.1371\/journal.pmed.1003769","volume":"18","author":"N Formica","year":"2021","unstructured":"Formica, N. et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLoS Med. 18, e1003769 (2021).","journal-title":"PLoS Med."},{"key":"35768_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 Vaccine. N. Engl. J. Med. 385, 1172\u20131183 (2021).","journal-title":"N. Engl. J. Med."},{"key":"35768_CR4","unstructured":"Nextstrain Team. Nexstrain. Genomic epidemiology of novel coronavirus\u2014global subsampling. https:\/\/nextstrain.org\/ncov\/gisaid\/global. (2021)."},{"key":"35768_CR5","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","volume":"34","author":"J Hadfield","year":"2018","unstructured":"Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34, 4121\u20134123 (2018).","journal-title":"Bioinformatics"},{"key":"35768_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2116185","volume":"386","author":"LM Dunkle","year":"2022","unstructured":"Dunkle, L. M. et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N. Engl. J. Med. 386, 531\u2013543 (2022).","journal-title":"N. Engl. J. Med."},{"key":"35768_CR7","unstructured":"World Health Organization. COVID-19 vaccines WHO EUL issued. accessed 10 Jun 2022; https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued"},{"key":"35768_CR8","unstructured":"European Medicines Agency. Nuvaxovid. Last updated 12 May 2022. accessed 6 Jun 2022; https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nuvaxovid"},{"key":"35768_CR9","unstructured":"VIPER Group COVID-19 Vaccine Tracker Team. COVID19 Vaccine Tracker. accessed 10 Jun 2022; https:\/\/covid19.trackvaccines.org\/vaccines\/approved\/"},{"key":"35768_CR10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"35768_CR11","doi-asserted-by":"crossref","unstructured":"Plotkin, S. A. & Gilbert, P. B. \u201cCorrelates of Protection\u201d in Plotkin\u2019s Vaccines (Seventh Edition). S.A. Plotkin, W.A. Orenstein, P.A. Offit, K.M. Edwards, Eds. (Elsevier, 2018).","DOI":"10.1016\/B978-0-323-35761-6.00003-1"},{"key":"35768_CR12","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","volume":"54","author":"SA Plotkin","year":"2012","unstructured":"Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615\u20131617 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"35768_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2034545","volume":"384","author":"SF Lumley","year":"2021","unstructured":"Lumley, S. F. et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N. Engl. J. Med. 384, 533\u2013540 (2021).","journal-title":"N. Engl. J. Med."},{"key":"35768_CR14","doi-asserted-by":"crossref","unstructured":"Addetia, A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J. Clin. Microbiol. 58, e02107-20 (2020).","DOI":"10.1128\/JCM.02107-20"},{"key":"35768_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"35768_CR16","doi-asserted-by":"publisher","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","volume":"373","author":"KS Corbett","year":"2021","unstructured":"Corbett, K. S. et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 373, eabj0299 (2021).","journal-title":"Science"},{"key":"35768_CR17","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.cell.2021.05.040","volume":"184","author":"X He","year":"2021","unstructured":"He, X. et al. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell 184, 3467\u20133473.e3411 (2021).","journal-title":"Cell"},{"key":"35768_CR18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","volume":"385","author":"MP O\u2019Brien","year":"2021","unstructured":"O\u2019Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N. Engl. J. Med. 385, 1184\u20131195 (2021).","journal-title":"N. Engl. J. Med."},{"key":"35768_CR19","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1056\/NEJMp2033538","volume":"384","author":"PR Krause","year":"2021","unstructured":"WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation, Krause, P. R. et al. Placebo-controlled trials of Covid-19 vaccines\u2014why we still need them. N. Engl. J. Med. 384, e2 (2021).","journal-title":"N. Engl. J. Med."},{"key":"35768_CR20","doi-asserted-by":"publisher","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326, https:\/\/doi.org\/10.1111\/imr.13091 (2022).","DOI":"10.1111\/imr.13091"},{"key":"35768_CR21","doi-asserted-by":"publisher","unstructured":"Khoury, D. S. et al. Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection. medRxiv. Posted 6 Jun 2022. Accessed 10 Jun 2022. https:\/\/doi.org\/10.1101\/2022.06.05.22275943.","DOI":"10.1101\/2022.06.05.22275943"},{"key":"35768_CR22","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41591-021-01484-6","volume":"27","author":"RA Koup","year":"2021","unstructured":"Koup, R. A. et al. A government-led effort to identify correlates of protection for COVID-19 vaccines. Nat. Med. 27, 1493\u20131494 (2021).","journal-title":"Nat. Med."},{"key":"35768_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"35768_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"35768_CR25","unstructured":"Fong, Y. et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol. 7, 1996\u20132010 (2022)."},{"key":"35768_CR26","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"key":"35768_CR27","doi-asserted-by":"publisher","unstructured":"USG COVID-19 Response Team\/Coronavirus Prevention Network (CoVPN) Biostatistics Team. USG COVID-19 response team\/CoVPN vaccine efficacy trial immune correlates statistical analysis plan. figshare. Online resource. Last updated 18 Apr, 2022. accessed 10 Jun 2022; https:\/\/doi.org\/10.6084\/m9.figshare.13198595.v13","DOI":"10.6084\/m9.figshare.13198595.v13"},{"key":"35768_CR28","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"35768_CR29","unstructured":"National Institute for Biological Standards and Control (NIBSC). Instructions for use of First WHO International Standard for anti-SARS-CoV-2 Immunoglobulin (Version 3.0, Dated 17\/12\/2020) NIBSC code: 20\/136. accessed 29 Jul 2021; https:\/\/www.nibsc.org\/science_and_research\/idd\/cfar\/covid-19_reagents.aspx"},{"key":"35768_CR30","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","volume":"397","author":"PA Kristiansen","year":"2021","unstructured":"Kristiansen, P. A. et al. WHO international standard for anti-SARS-CoV-2 immunoglobulin. Lancet 397, 1347\u20131348 (2021).","journal-title":"Lancet"},{"key":"35768_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03154-6","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci. Rep. 11, 23921 (2021).","journal-title":"Sci. Rep."},{"key":"35768_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881\u2013891 (2021).","journal-title":"Lancet"},{"key":"35768_CR33","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52\u2013e61 (2022).","journal-title":"Lancet Microbe"},{"key":"35768_CR34","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"35768_CR35","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1002\/sim.7927","volume":"37","author":"D Follmann","year":"2018","unstructured":"Follmann, D. Reliably picking the best endpoint. Stat. Med. 37, 4374\u20134385 (2018).","journal-title":"Stat. Med."},{"key":"35768_CR36","doi-asserted-by":"publisher","unstructured":"Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. bioRxiv, https:\/\/doi.org\/10.1101\/2022.03.18.484953 (2022).","DOI":"10.1101\/2022.03.18.484953"},{"key":"35768_CR37","doi-asserted-by":"publisher","first-page":"100405","DOI":"10.1016\/j.xcrm.2021.100405","volume":"2","author":"MJ Gorman","year":"2021","unstructured":"Gorman, M. J. et al. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Rep. Med. 2, 100405 (2021).","journal-title":"Cell Rep. Med."},{"key":"35768_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/biomet\/73.1.1","volume":"73","author":"RL Prentice","year":"1986","unstructured":"Prentice, R. L. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73, 1\u201311 (1986).","journal-title":"Biometrika"},{"key":"35768_CR39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2202\/1544-6115.1309","volume":"6","author":"MJ van der Laan","year":"2007","unstructured":"van der Laan, M. J., Polley, E. C. & Hubbard, A. E. Super learner. Stat. Appl Genet. Mol. Biol. 6, 25 (2007).","journal-title":"Stat. Appl Genet. Mol. Biol."},{"key":"35768_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1515\/ijb-2015-0013","volume":"12","author":"AE Hubbard","year":"2016","unstructured":"Hubbard, A. E., Kherad-Pajouh, S. & van der Laan, M. J. Statistical inference for data adaptive target parameters. Int. J. Biostat. 12, 3\u201319 (2016).","journal-title":"Int. J. Biostat."},{"key":"35768_CR41","doi-asserted-by":"publisher","unstructured":"Williamson, B., Gilbert, P. B., Simon, N. & Carone, M. A General framework for inference on algorithm-agnostic variable importance. J. Am. Stat. Assoc. https:\/\/doi.org\/10.1080\/01621459.2021.2003200. (2022).","DOI":"10.1080\/01621459.2021.2003200"},{"key":"35768_CR42","doi-asserted-by":"crossref","unstructured":"Lumley, T. Complex Surveys: A Guide to Analysis Using R (vol. 565, John Wiley & Sons, 2010).","DOI":"10.1002\/9780470580066"},{"key":"35768_CR43","volume-title":"R: A Language and Environment for Statistical Computing.","author":"R Core Team.","year":"2022","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria, 2022. https:\/\/www.R-project.org\/"},{"key":"35768_CR44","doi-asserted-by":"publisher","unstructured":"van der Laan, L., Zhang, W. & Gilbert, P. B. Nonparametric estimation of the causal effect of a stochastic threshold-based intervention. https:\/\/doi.org\/10.1111\/biom.13690. Biometrics, 1\u201322 (2022).","DOI":"10.1111\/biom.13690"},{"key":"35768_CR45","doi-asserted-by":"publisher","unstructured":"Gilbert, P. B., Fong, Y., Kenny, A. & Carone, M. A controlled effects approach to assessing immune correlates of protection. kxac024, https:\/\/doi.org\/10.1093\/biostatistics\/kxac24. Biostatistics (2022).","DOI":"10.1093\/biostatistics\/kxac24"},{"key":"35768_CR46","unstructured":"Westfall, P. H. & Young, S. S. Resampling-based multiple testing: examples and methods for P value adjustment (vol. 279, Wiley Series in Probability and Statistics, John Wiley & Sons, 1993)."},{"key":"35768_CR47","doi-asserted-by":"publisher","unstructured":"Gilbert, P. B. et al. Immune Correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.7430761. 2022.","DOI":"10.5281\/zenodo.7430761."}],"updated-by":[{"DOI":"10.1038\/s41467-023-37367-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35768-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35768-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35768-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T03:09:36Z","timestamp":1679540976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35768-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35768"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-35768-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.22.22276362","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"11 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-023-37367-2","URL":"https:\/\/doi.org\/10.1038\/s41467-023-37367-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have completed the ICMJE uniform disclosure form at\n                      \n                      . P.B.G., Y.F., Y.H., D.B., Y.L., C.Y., B.B., L.W.P.v.d.L., A.K.R., M.P.A., J.G.K., L.C., and L.N.C. declare support (in the form of grant payments to their institutions) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) for the submitted work. Y.H. additionally declares contract payments to her institution within the past 36 months from the World Health Organization to conduct statistical analysis work related to COVID-19 vaccines (outside the scope of the current work), as well as direct payment (approved by her institute) within the past 36 months from Worcester HIV Vaccine for participation on a Data Safety Monitoring Board or Advisory Board. L.D., G.A., I.C., W.W., and A.M. are stockholders and employees at Novavax, Inc. C.J.P. declares support from BARDA and the US Centers for Disease Control within the past 36 months, for SARS-CoV-2 nAb testing for vaccine trials and surveillance studies, respectively, and is a shareholder in Labcorp (LH) and in Novavax (NVAX). N.S.H. declares a grant from the National Science Foundation within the past 36 months paid to his institution. K.M.N. declares grants within the past 36 months from Pfizer to her institution to conduct clinical trials of COVID-19 vaccines (but receives no salary support from these grants), as well as grants from the NIH to participate in the overall organization of COVID-19 vaccine trials and for participation in vaccine trials. K.L.K. declares support in the form of grant payments to her institution for the submitted work; serving as the PREVENT-19 Trial co-chair, CoVPN, with salary support from the NIH paid to her institution within the past 36 months; as well as PCR Cepheid and Abbott equipment for volunteer testing from CoVPN within the past 36 months (payments to her institution; will be returned). C.L.G. is a site Principal Investigator and a CoVPN protocol co-chair for the Novavax phase 3 trial. Her institution receives grant funding from NIH that includes salary support for her from NIAID for these activities. All other authors declare no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"331"}}